BriaCell Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
BriaCell Therapeutics has a total shareholder equity of $-6.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $6.2M and $12.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$935.69k |
| Equity | -US$6.23m |
| Total liabilities | US$12.44m |
| Total assets | US$6.20m |
Recent financial health updates
Recent updates
BriaCell stock rises on license deal for anti-cancer agent
Aug 04BriaCell partners with Waisman Biomanufacturing to make & supply prostate cancer therapy
Jul 05BriaCell, Harvard enter research agreement to identify targets for cancer treatments
Jun 29BriaCell Therapeutics receives proceed of $12.88M from warrant exercises
Jun 10BriaCell Therapeutics skyrockets 104% on robust overall survival benefit in advanced breast cancer patients
Jun 02Financial Position Analysis
Short Term Liabilities: BCTX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: BCTX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: BCTX is debt free.
Reducing Debt: BCTX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BCTX has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: BCTX is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.